Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model
Crossref DOI link: https://doi.org/10.1007/s00259-014-2798-3
Published Online: 2014-05-24
Published Print: 2014-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Grünberg, Jürgen
Lindenblatt, Dennis
Dorrer, Holger
Cohrs, Susan
Zhernosekov, Konstantin
Köster, Ulli
Türler, Andreas
Fischer, Eliane
Schibli, Roger
Text and Data Mining valid from 2014-05-24